Abstract:Background: Little is known about paediatric pulmonary arterial hypertension (PAH) in low- and middle-income countries (LMICs). We sought to investigate clinical characteristics, treatment patterns and survival statistics for paediatric PAH in China between 2006 and 2018.Methods: We collected and analyzed data from a registry which consecutively recruited newly diagnosed PAH patients aged 3 months to 18 years between 2006 and 2016 from 2 major national referral centers in China, and followed them through 2018. The main outcome was the time from diagnosis to the occurrence of death or lung transplantation.Findings: 348 patients (median age 10·6 years, 60·1% female) were followed-up for a median of 6·3 years. Among them, PAH associated with congenital heart disease (APAH-CHD) was confirmed in 208 (59·8%) patients; 62 (57.9%) with unrepaired APAH-CHD had not been identified as having CHD before the diagnosis of PAH. In patients with repaired defects, the defects were closed at a median age of 7·0 (3·8-14·3) years. The 5- and 10-year transplantation-free survival for all patients was 75·4 ± 2·4% and 60·9 ± 3·6%. The survival rates were lowest in idiopathic/heritable PAH (IPAH/HPAH) (5-year 58·2 ± 5·2%, 10-year 29·4% ± 8·2% with median survival of 5·7 years), followed by APAH-CHD (5-year 82·3 ± 2·7%, 10-year 69·2 ± 4·5), and positive responders (5-year 96·0 ± 3·9%, 10-year 96·0 ± 3·9%) (P<0·001 at 5-year, 10-year, respectively). From 2006-2011 and from 2012-2016, children received incrementally more aggressive targeted therapies for PAH treatment (initial traditional therapy: 23.2% vs 8.0%; initial targeted combination therapy: 23.2% vs 57.7%, both P<0.001), however, parenteral prostanoids were only used in 4.9% of patients. These trends in targeted therapy were consistent with the upward trends of survival during study period: PAH diagnosed after 2011 (vs 2006-2011, Hazard Ratio 0·49, [95% CI 0·28-0·85], P=0·01) was an independent predictor for improved transplantation-free survival.Interpretation APAH-CHD was a heavy burden in China, attributed to significantly delayed diagnosis and poor management of CHD in childhood. A clear improvement of overall transplantation-free survival was observed for patients diagnosed after 2011, possibly due to the more aggressive targeted therapy treatment. Findings from this study should provide an important basis for policy making of priority areas for the medical care of pediatric PAH in LMICs.Funding: This study was supported by the National Key Research and Development Program of China (2016YFC0901502, 2016YFC0901500), the Key Program of Beijing Municipal Natural Science Foundation (7181009), National Science Fund for Distinguished Young Scholars (81425002), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-002, 2017-I2M-1-004, 2017-I2M-2-001), the Key Program of National Natural Science Foundation of China (81630003).Declaration of Interests: We declare no competing interests.Ethical Approval Statement: This study was approved by the local Ethics Committees. Written informed consent was obtained from parents or legal guardians.

The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease

Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study

The effection of idiopathic pulmonary hypertension on endothelial progenitor cells and bone morphogenetic protein-2

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension.

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

Levels of plasma endothelin and calcitonin gene-related peptide in children with congenital heart disease and pulmonary hypertension

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

[Changes of endothelial progenitor cells from peripheral blood in patients with coronary heart diseases].

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Correlation of serum levels of VEGF and SDF-1 with the number and function of circulating EPCs in children with cyanotic congenital heart disease

Modulation of EPC: A New Hope for Pulmonary Artery Hypertension Treatment

Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors

Association Study of Circulating Endothelial Cells and Clinical Outcome of Pulmonary Hypertension Secondary to Congenital Heart Disease

Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry

Changes of Circulating Endothelial Progenitor Cells in Patients with Cyanotic Congenital Heart Diseases

Hemodynamic Analysis Of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: A Numerical Study Of Patient-Specific Models

Pulmonary arterial hypertension associated with congenital heart disease in children: clinical characterisation, outcomes and changes in demographics over time

Echocardiographic Insights into Pulmonary Arterial Hypertension: the Advantage of Congenital Heart Disease Patients

Changes in Complement Factor H-related Protein 2 in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease and Its Potential Clinical Significance

Paediatric Pulmonary Arterial Hypertension in China During 2006-18: Insights from a Longitudinal Registry Study